All Updates

All Updates

icon
Filter
Partnerships
Clearmind Medicine and Yissum expand collaboration for psychedelic compound patent
Psychedelic Medicine
Aug 16, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Aug 16, 2024

Clearmind Medicine and Yissum expand collaboration for psychedelic compound patent

Partnerships

  • Clearmind Medicine, a Vancouver-based psychedelic drugs company, and Yissum, the technology transfer company of Hebrew University, have expanded their collaboration through a new patent application.

  • The companies submitted an international Patent Cooperation Treaty (PCT) application for generation 3.0 psychedelic compounds, their preparation methods, and their use in treating mental disorders. The patent, if approved, would secure intellectual property rights for Clearmind under its exclusive global license agreement with Yissum. The companies aim to develop advanced psychedelic molecules as potential treatments for mental disorders, with plans to seek patent protection in major jurisdictions like the US, Europe, China, and India.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.